Details of Drug

Drug General Information (ID: D1272)
Drug Name	Phenyl salicylate
Drug Type	Small molecule
Drug Synonymous	Phenyl salicylate; 118-55-8; PHENYL 2-HYDROXYBENZOATE; Salol; Phenol salicylate; Salphenyl; Musol; Benzoic acid, 2-hydroxy-, phenyl ester; 2-Phenoxycarbonylphenol; Salicylic acid, phenyl ester; 2-Hydroxybenzoic acid phenyl ester; Phenyl-2-hydroxybenzoate; 2-Hydroxy-benzoic acid phenyl ester; Fenylester kyseliny salicylove; NSC 33406; Salicylic Acid Phenyl Ester; UNII-28A37T47QO; Seesorb 201; Seesorb K 201; 2-Hydroxybenzoic acid, phenyl ester; MFCD00002213; NSC-33406; CHEBI:34918; 28A37T47QO; NSC33406; NCGC00090887-02; DSSTox_CID_1957; DSSTox_RID_76426; DSSTox_GSID_21957; CAS-118-55-8; CCRIS 4859; Phenyl salicylate [NF]; EINECS 204-259-2; Fenylester kyseliny salicylove [Czech]; BRN 0393969; phenylsalicylate; AI3-00195; phenyl-salicylate; salicylic acid phenyl; salicylic phenyl ester; WLN: QR BVOR; Oprea1_020651; Oprea1_771794; SCHEMBL24326; BIDD:ER0018; CHEMBL1339216; DTXSID6021957; FEMA NO. 3960; ZINC38545; Phenyl salicylate, >=99%, FG; STR06361; Tox21_113459; Tox21_201811; Tox21_302949; Phenyl Salicylate, Crystal, Purified; STK052177; AKOS000121203; NSC33406NSC 33406; Tox21_113459_1; DB11071; MCULE-3642683340; PS-7960; Phenyl salicylate melting point standard; NCGC00090887-01; NCGC00090887-03; NCGC00090887-04; NCGC00090887-05; NCGC00091499-03; NCGC00256612-01; NCGC00259360-01; AC-11469; M822; Phenyl salicylate, ReagentPlus(R), 99%; DB-024372; FT-0689174; S0017; AB00443435-03; A804056; Phenyl salicylate, Vetec(TM) reagent grade, 98%; Q421259; SR-01000883691; J-200110; SR-01000883691-1; Z57206005; Mettler-Toledo Calibration substance ME 30034252, Phenyl salicylate; Mettler-Toledo Calibration substance ME 30034252, Phenyl salicylate, traceable to primary standards; Phenyl salicylate melting point standard, approximately 41 degrees, United States Pharmacopeia (USP) Reference Standard; Phenyl salicylate melting point standard, Pharmaceutical Secondary Standard; Certified Reference Material Click to Show/Hide
Therapeutic Class	Salicylates
Structure
Structure	3D Structure		2D Structure
Formula	C13H10O3
InChI	InChI=1S/C13H10O3/c14-12-9-5-4-8-11(12)13(15)16-10-6-2-1-3-7-10/h1-9,14H
InChIKey	ZQBAKBUEJOMQEX-UHFFFAOYSA-N
Canonical SMILES	C1=CC=C(C=C1)OC(=O)C2=CC=CC=C2O
External Link
External Link	Pubchem ID	8361

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM001 Affected gastrointestinal absorption AM003 Affected organization distribution AM005 Affected excretion pathways AM006 Pharmacodynamic additive effects AM007 Pharmacodynamic antagonistic effects BM005 Altered gastric pH BM013 Competitive binding of plasma proteins BM027 Decreased renal excretion due to nephrotoxicity BM029 Altered urine pH BM032 Decreased renal excretion (Unspecific) BM039 Additive CNS stimulant effects BM050 Increased risk of bleeding BM054 Increased risk of GI mucosal injury/bleeding risk BM055 Increased risk of hepatotoxicity BM058 Increased risk of hyperkalemia BM064 Increased risk of hypoglycemia BM070 Increased risk of metabolic acidosis BM072 Increased risk of nephrotoxicity BM089 Antagonize the effect of antihypertensive agents BM099 Antagonize the effect of uricosuric agents BM107 Attenuated pharmacological effects (Unspecific) BM109 Increased risk of other adverse reactions (Unspecific)
Relation Graph

Full list of drugs interacting with Phenyl salicylate
Affected gastrointestinal absorption
	Altered gastric pH					Drug Num: 6
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0458		Dexlansoprazole	C16H14F3N3O2S	9578005	Minor		Inter Info	[88], [89], [90]
D0603		Esomeprazole	C17H19N3O3S	9568614	Minor		Inter Info	[88], [89], [90]
D0892		Lansoprazole	C16H14F3N3O2S	3883	Minor		Inter Info	[88], [89], [90]
D1179		Omeprazole	C17H19N3O3S	4594	Minor		Inter Info	[88], [89], [90]
D1222		Pantoprazole	C16H15F2N3O4S	4679	Minor		Inter Info	[88], [89], [90]
D1373		Rabeprazole	C18H21N3O3S	5029	Minor		Inter Info	[88], [89], [90]
Affected organization distribution
	Competitive binding of plasma proteins					Drug Num: 3
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0207		Brinzolamide (ophthalmic)	C12H21N3O5S3	68844	Major		Inter Info	[1], [2], [3]
D0521		Dorzolamide (ophthalmic)	C10H16N2O4S3	5284549	Major		Inter Info	[1], [2], [3]
D1677		Valproic acid	C8H16O2	3121	Moderate		Inter Info	[79], [80], [81]
Affected excretion pathways
	Decreased renal excretion due to nephrotoxicity					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1241		Pemetrexed	C20H21N5O6	135410875	Moderate		Inter Info	[69], [70], [71]
	Altered urine pH					Drug Num: 2
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0483		Didanosine	C10H12N4O3	135398739	Moderate		Inter Info	[47], [48], [49]
D0968		Magnesium carbonate	CMgO3	11029	Moderate		Inter Info	[47], [48], [49]
	Decreased renal excretion (Unspecific)					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0491		Digoxin	C41H64O14	2724385	Moderate		Inter Info	[50], [51], [52]
Pharmacodynamic additive effects
	Additive CNS stimulant effects					Drug Num: 14
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0340		Cinoxacin	C12H10N2O5	2762	Moderate		Inter Info	[40], [41], [42]
D0341		Ciprofloxacin	C17H18FN3O3	2764	Moderate		Inter Info	[40], [41], [42]
D0573		Enoxacin	C15H17FN4O3	3229	Moderate		Inter Info	[40], [41], [42]
D0712		Gatifloxacin	C19H22FN3O4	5379	Moderate		Inter Info	[40], [41], [42]
D0716		Gemifloxacin	C18H20FN5O4	9571107	Moderate		Inter Info	[40], [41], [42]
D0740		Grepafloxacin	C19H22FN3O3	72474	Moderate		Inter Info	[40], [41], [42]
D0943		Lomefloxacin	C17H19F2N3O3	3948	Moderate		Inter Info	[40], [41], [42]
D1092		Moxifloxacin	C21H24FN3O4	152946	Moderate		Inter Info	[40], [41], [42]
D1102		Nalidixic acid	C12H12N2O3	4421	Moderate		Inter Info	[40], [41], [42]
D1155		Norfloxacin	C16H18FN3O3	4539	Moderate		Inter Info	[40], [41], [42]
D1165		Ofloxacin	C18H20FN3O4	4583	Moderate		Inter Info	[40], [41], [42]
D0438		Delafloxacin	C18H12ClF3N4O4	487101	Moderate		Inter Info	[40], [41], [42]
D1499		Sparfloxacin	C19H22F2N4O3	60464	Moderate		Inter Info	[40], [41], [42]
D1657		Trovafloxacin	C20H15F3N4O3	62959	Moderate		Inter Info	[40], [41], [42]
	Increased risk of bleeding					Drug Num: 35
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1380		Ramucirumab	NA	NA	Major		Inter Info	[10]
D0047		Alteplase	NA	NA	Moderate		Inter Info	[20], [21], [22]
D0087		Anisindione	C16H12O3	2197	Moderate		Inter Info	[29], [30], [31]
D0088		Anistreplase	NA	NA	Moderate		Inter Info	[20], [21], [22]
D0096		Apixaban	C25H25N5O4	10182969	Moderate		Inter Info	[29], [30], [31]
D0102		Ardeparin	C26H42N2O37S5	772	Moderate		Inter Info	[29], [30], [31]
D0104		Argatroban	C23H36N6O5S	92722	Moderate		Inter Info	[29], [30], [31]
D0189		Bivalirudin	C98H138N24O33	16129704	Moderate		Inter Info	[29], [30], [31]
D0364		Clopidogrel	C16H16ClNO2S	60606	Moderate		Inter Info	[43], [44]
D0414		Dalteparin	C26H42N2O37S5	772	Moderate		Inter Info	[29], [30], [31]
D0415		Danaparoid	NA	NA	Moderate		Inter Info	[29], [30], [31]
D0481		Dicoumarol	C19H12O6	54676038	Moderate		Inter Info	[29], [30], [31]
D0537		Drotrecogin alfa	NA	NA	Moderate		Inter Info	[29], [30], [31]
D0551		Edoxaban	C24H30ClN7O4S	10280735	Moderate		Inter Info	[29], [30], [31]
D0574		Enoxaparin	C26H42N2O37S5	772	Moderate		Inter Info	[29], [30], [31]
D0586		Epoprostenol	C20H32O5	5282411	Moderate		Inter Info	[57], [58], [59]
D0588		Eptifibatide	C35H49N11O9S2	448812	Moderate		Inter Info	[60], [43], [61]
D0690		Fondaparinux	C31H53N3O49S8	5282448	Moderate		Inter Info	[29], [30], [31]
D0753		Heparin	C26H42N2O37S5	772	Moderate		Inter Info	[29], [30], [31]
D0792		Iloprost	C22H32O4	5311181	Moderate		Inter Info	[57], [58], [59]
D0904		Lepirudin	C287H440N80O111S6	118856773	Moderate		Inter Info	[29], [30], [31]
D0176		Betrixaban	C23H22ClN5O3	10275777	Moderate		Inter Info	[29], [30], [31]
D0447		Desirudin	C287H440N80O110S6	16129703	Moderate		Inter Info	[29], [30], [31]
D1328		Prasugrel	C20H20FNO3S	6918456	Moderate		Inter Info	[75]
D1395		Reteplase	NA	NA	Moderate		Inter Info	[20], [21], [22]
D1417		Rivaroxaban	C19H18ClN3O5S	9875401	Moderate		Inter Info	[29], [30], [31]
D1506		Streptokinase	C11H19NO2	9815560	Moderate		Inter Info	[20], [21], [22]
D1550		Tenecteplase	NA	NA	Moderate		Inter Info	[20], [21], [22]
D1579		Ticagrelor	C23H28F2N6O4S	9871419	Moderate		Inter Info	[17], [78]
D1588		Tinzaparin	C26H42N2O37S5	772	Moderate		Inter Info	[29], [30], [31]
D1593		Tirofiban	C22H36N2O5S	60947	Moderate		Inter Info	[60], [43], [61]
D1625		Treprostinil	C23H34O5	6918140	Moderate		Inter Info	[57], [58], [59]
D1669		Urokinase	NA	NA	Moderate		Inter Info	[20], [21], [22]
D1711		Warfarin	C19H16O4	54678486	Moderate		Inter Info	[29], [30], [31]
D0368		Clove	NA	NA	Minor		Inter Info	[85], [86], [87]
	Increased risk of GI mucosal injury/bleeding risk					Drug Num: 18
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0882		Ketorolac	C15H13NO3	3826	Major		Inter Info	[6]
D0034		Alendronic acid	C4H13NO7P2	2088	Moderate		Inter Info	[14], [15], [16]
D0172		Betamethasone	C22H29FO5	9782	Moderate		Inter Info	[37], [38], [39]
D0215		Budesonide	C25H34O6	5281004	Moderate		Inter Info	[37], [38], [39]
D0453		Dexamethasone	C22H29FO5	5743	Moderate		Inter Info	[37], [38], [39]
D0623		Etidronic acid	C2H8O7P2	3305	Moderate		Inter Info	[14], [15], [16]
D0671		Fludrocortisone	C21H29FO5	31378	Moderate		Inter Info	[37], [38], [39]
D0773		Hydrocortisone	C21H30O5	5754	Moderate		Inter Info	[37], [38], [39]
D0783		Ibandronate	C9H23NO7P2	60852	Moderate		Inter Info	[14], [15], [16]
D1041		Methylprednisolone	C22H30O5	6741	Moderate		Inter Info	[37], [38], [39]
D0436		Deflazacort	C25H31NO6	189821	Moderate		Inter Info	[37], [38], [39]
D1332		Prednisolone	C21H28O5	5755	Moderate		Inter Info	[37], [38], [39]
D1334		Prednisone	C21H26O5	5865	Moderate		Inter Info	[37], [38], [39]
D1412		Risedronic acid	C7H11NO7P2	5245	Moderate		Inter Info	[14], [15], [16]
D1584		Tiludronic acid	C7H9ClO6P2S	60937	Moderate		Inter Info	[14], [15], [16]
D1628		Triamcinolone	C21H27FO6	31307	Moderate		Inter Info	[37], [38], [39]
D1630		Triamcinolone (ophthalmic)	C21H27FO6	31307	Moderate		Inter Info	[37], [38], [39]
D1727		Zoledronic acid	C5H10N2O7P2	68740	Moderate		Inter Info	[14], [15], [16]
	Increased risk of hepatotoxicity					Drug Num: 2
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0900		Leflunomide	C12H9F3N2O2	3899	Major		Inter Info	[7], [8], [9]
D1556		Teriflunomide	C12H9F3N2O2	54684141	Major		Inter Info	[7], [8], [9]
	Increased risk of hyperkalemia					Drug Num: 2
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0536		Drospirenone	C24H30O3	68873	Moderate		Inter Info	[53], [54]
D0585		Eplerenone	C24H30O6	443872	Moderate		Inter Info	[33], [55], [56]
	Increased risk of hypoglycemia					Drug Num: 23
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0013		Acetohexamide	C15H20N2O4S	1989	Moderate		Inter Info	[11], [12], [13]
D0325		Chlorpropamide	C10H13ClN2O3S	2727	Moderate		Inter Info	[11], [12], [13]
D0727		Glimepiride	C24H34N4O5S	3476	Moderate		Inter Info	[11], [12], [13]
D0728		Glipizide	C21H27N5O4S	3478	Moderate		Inter Info	[11], [12], [13]
D0730		Glyburide	C23H28ClN3O5S	3488	Moderate		Inter Info	[11], [12], [13]
D0807		Insulin aspart (aspart protamine)	C256H381N65O79S6	118984445	Moderate		Inter Info	[63], [64], [65]
D0808		Insulin aspart (aspart)	C256H381N65O79S6	118984445	Moderate		Inter Info	[63], [64], [65]
D0809		Insulin degludec	C274H411N65O81S6	118984462	Moderate		Inter Info	[63], [64], [65]
D0810		Insulin detemir	C267H402N64O76S6	16137271	Moderate		Inter Info	[63], [64], [65]
D0811		Insulin glargine	C267H404N72O78S6	118984454	Moderate		Inter Info	[63], [64], [65]
D0812		Insulin glulisine	C258H384N64O78S6	16136701	Moderate		Inter Info	[63], [64], [65]
D0813		Insulin human	C257H383N65O77S6	118984375	Moderate		Inter Info	[63], [64], [65]
D0814		Insulin human (inhalation, rapid acting)	C257H383N65O77S6	118984375	Moderate		Inter Info	[63], [64], [65]
D0815		Insulin human (isophane)	C257H383N65O77S6	118984375	Moderate		Inter Info	[63], [64], [65]
D0816		Insulin human (regular)	C257H383N65O77S6	118984375	Moderate		Inter Info	[63], [64], [65]
D0817		Insulin human (zinc extended)	C257H383N65O77S6	118984375	Moderate		Inter Info	[63], [64], [65]
D0818		Insulin human (zinc)	C257H383N65O77S6	118984375	Moderate		Inter Info	[63], [64], [65]
D0819		Insulin lispro	C257H389N65O77S6	16132438	Moderate		Inter Info	[63], [64], [65]
D0820		Insulin lispro (protamine)	C257H389N65O77S6	16132438	Moderate		Inter Info	[63], [64], [65]
D1112		Nateglinide	C19H27NO3	5311309	Moderate		Inter Info	[11], [12], [13]
D1392		Repaglinide	C27H36N2O4	65981	Moderate		Inter Info	[11], [12], [13]
D1601		Tolazamide	C14H21N3O3S	5503	Moderate		Inter Info	[11], [12], [13]
D1603		Tolbutamide	C12H18N2O3S	5505	Moderate		Inter Info	[11], [12], [13]
	Increased risk of nephrotoxicity					Drug Num: 10
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0432		Deferasirox	C21H15N3O4	214348	Major		Inter Info	[4], [5]
D0056		Amikacin	C22H43N5O13	37768	Moderate		Inter Info	[23], [24], [25]
D0057		Amikacin (liposome)	C22H43N5O13	37768	Moderate		Inter Info	[23], [24], [25]
D0402		Cyclosporine	C62H111N11O12	5284373	Moderate		Inter Info	[45], [27], [46]
D0718		Gentamicin	C21H43N5O7	3467	Moderate		Inter Info	[23], [24], [25]
D0876		Kanamycin	C18H36N4O11	6032	Moderate		Inter Info	[23], [24], [25]
D1126		Netilmicin	C21H41N5O7	441306	Moderate		Inter Info	[23], [24], [25]
D1304		Plazomicin	C25H48N6O10	42613186	Moderate		Inter Info	[23], [24], [25]
D1507		Streptomycin	C21H39N7O12	19649	Moderate		Inter Info	[23], [24], [25]
D1597		Tobramycin	C18H37N5O9	36294	Moderate		Inter Info	[23], [24], [25]
	Increased risk of other adverse reactions (Unspecific)					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1308		Polyethylene glycol (3350 with electrolytes)	C2H6O2	174	Moderate		Inter Info	[72], [73], [74]
Pharmacodynamic antagonistic effects
	Antagonize the effect of antihypertensive agents					Drug Num: 29
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0038		Aliskiren	C30H53N3O6	5493444	Moderate		Inter Info	[17], [18], [19]
D0069		Amlodipine	C20H25ClN2O5	2162	Moderate		Inter Info	[26], [27], [28]
D0138		Azilsartan medoxomil	C30H24N4O8	135409642	Moderate		Inter Info	[32], [6], [33]
D0156		Benazepril	C24H28N2O5	5362124	Moderate		Inter Info	[34], [35], [36]
D0170		Bepridil	C24H34N2O	2351	Moderate		Inter Info	[26], [27], [28]
D0497		Diltiazem	C22H26N2O4S	39186	Moderate		Inter Info	[26], [27], [28]
D0567		Enalapril	C20H28N2O5	5388962	Moderate		Inter Info	[34], [35], [36]
D0587		Eprosartan	C23H24N2O4S	5281037	Moderate		Inter Info	[32], [6], [33]
D0640		Felodipine	C18H19Cl2NO4	3333	Moderate		Inter Info	[26], [27], [28]
D0695		Fosinopril	C30H46NO7P	55891	Moderate		Inter Info	[34], [35], [36]
D0770		Hydralazine	C8H8N4	3637	Moderate		Inter Info	[62]
D0844		Irbesartan	C25H28N6O	3749	Moderate		Inter Info	[32], [6], [33]
D0865		Isradipine	C19H21N3O5	3784	Moderate		Inter Info	[26], [27], [28]
D0911		Levamlodipine	C20H25ClN2O5	9822750	Moderate		Inter Info	[26], [27], [28]
D0938		Lisinopril	C21H31N3O5	5362119	Moderate		Inter Info	[34], [35], [36]
D0954		Losartan	C22H23ClN6O	3961	Moderate		Inter Info	[32], [6], [33]
D1082		Moexipril	C27H34N2O7	91270	Moderate		Inter Info	[34], [35], [36]
D1130		Nicardipine	C26H29N3O6	4474	Moderate		Inter Info	[26], [27], [28]
D1134		Nifedipine	C17H18N2O6	4485	Moderate		Inter Info	[26], [27], [28]
D1138		Nimodipine	C21H26N2O7	4497	Moderate		Inter Info	[26], [27], [28]
D1141		Nisoldipine	C20H24N2O6	4499	Moderate		Inter Info	[26], [27], [28]
D1170		Olmesartan	C24H26N6O3	158781	Moderate		Inter Info	[32], [6], [33]
D1256		Perindopril	C19H32N2O5	107807	Moderate		Inter Info	[34], [35], [36]
D1369		Quinapril	C25H30N2O5	54892	Moderate		Inter Info	[34], [35], [36]
D1379		Ramipril	C23H32N2O5	5362129	Moderate		Inter Info	[34], [35], [36]
D1545		Telmisartan	C33H30N4O2	65999	Moderate		Inter Info	[32], [6], [33]
D1618		Trandolapril	C24H34N2O5	5484727	Moderate		Inter Info	[34], [35], [36]
D1679		Valsartan	C24H29N5O3	60846	Moderate		Inter Info	[32], [6], [33]
D1690		Verapamil	C27H38N2O4	2520	Moderate		Inter Info	[26], [27], [28]
	Antagonize the effect of uricosuric agents					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1341		Probenecid	C13H19NO4S	4911	Moderate		Inter Info	[17], [76], [77]
	Attenuated pharmacological effects (Unspecific)					Drug Num: 6
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1822		Iodide I-123	I-	135300	Moderate		Inter Info	[66], [67], [68]
D0217		Bumetanide	C17H20N2O5S	2471	Minor		Inter Info	[82], [83], [84]
D0613		Etacrynic acid	C13H12Cl2O4	3278	Minor		Inter Info	[82], [83], [84]
D0704		Furosemide	C12H11ClN2O5S	3440	Minor		Inter Info	[82], [83], [84]
D1812		Hyaluronidase	C17H24BrNO2	91820602	Minor		Inter Info	[91], [92], [93]
D1611		Torasemide	C16H20N4O3S	41781	Minor		Inter Info	[82], [83], [84]

References
1	Cowan RA, Hartnell GG, Lowdell CP, Baird IM, Leak AM "Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in patients with normal renal function." Br Med J (Clin Res Ed) 289 (1984): 347-8. [PMID: 6432091]
2	Sweeney KR, Chapron DJ, Brandt JL, Gomolin IH, Feig PU, Kramer PA "Toxic interaction between acetazolamide and salicylate: case reports and a pharmacokinetic explanation." Clin Pharmacol Ther 40 (1986): 518-24. [PMID: 3769383]
3	Sweeney KR, Chapron DJ, Kramer PA "Effect of salicylate on serum protein binding and red blood cell uptake of acetazolamide in vitro." J Pharm Sci 77 (1988): 751-6. [PMID: 3225768]
4	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
5	Rafat C, Fakhouri F, Ribeil JA, Delarue R, Le Quintrec M "Fanconi Syndrome Due to Deferasirox." Am J Kidney Dis (2009):. [PMID: 19493602]
6	Product Information. Toradol (ketorolac). Roche Laboratories, Nutley, NJ.
7	EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
8	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
9	Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
10	Product Information. Cyramza (ramucirumab). Eli Lilly and Company, Indianapolis, IN.
11	Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301. [PMID: 14071924]
12	Field JB, Ohta M, Boyle C, Remer A "Potentiation of acetohexamide hypoglycemia by phenylbutazone." N Engl J Med 277 (1967): 889-94. [PMID: 6061822]
13	Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67. [PMID: 4749404]
14	Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
15	Product Information. Bonefos (clodronate). Rhone-Poulenc Rorer Canada Inc, Laval, QC.
16	Product Information. Didronel I.V. Infusion (etidronate). MGI Pharma Inc, Minnetonka, MN.
17	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
18	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
19	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA."
20	Harder S, Klinkhardt U "Thrombolytics: drug interactions of clinical significance." Drug Saf 23 (2000): 391-9. [PMID: 11085346]
21	Product Information. Abbokinase (urokinase). Abbott Pharmaceutical, Abbott Park, IL.
22	Product Information. TNKase (tenecteplase) Genentech, South San Francisco, CA.
23	Farag MM, Mikhail MR, Abdel-Meguid E, Abdel-Tawab S "Assessment of gentamicin-induced nephrotoxicity in rats treated with low doses of ibuprofen and diclofenac sodium." Clin Sci 91 (1996): 187-91. [PMID: 8795442]
24	Gagliardi L "Possible indomethacin-aminoglycoside interaction in preterm infants." J Pediatr 107 (1985): 991-2. [PMID: 4067765]
25	Scott CS, RetschBogart GZ, Henry MM "Renal failure and vestibular toxicity in an adolescent with cystic fibrosis receiving gentamicin and standard-dose ibuprofen." Pediat Pulm 31 (2001): 314-6. [PMID: 11288217]
26	Deleeuw PW "Nonsteroidal anti-inflammatory drugs and hypertension: the risks in perspective." Drugs 51 (1996): 179-87. [PMID: 8808162]
27	Product Information. Arthrotec (diclofenac-misoprostol). Searle, Skokie, IL.
28	Ring ME, Corrigan JJ, Fenster PE "Effects of oral diltiazem on platelet function: alone and in combination with "low dose" aspirin." Thromb Res 44 (1986): 391-400. [PMID: 3798404]
29	Fausa O "Salicylate-induced hypoprothrombinemia: a report of four cases." Acta Med Scand 188 (1970): 403-8. [PMID: 5490567]
30	Koch-Weser J, Sellers EM "Drug interactions with coumarin anticoagulants (first of two parts)." N Engl J Med 285 (1971): 487-98. [PMID: 4397794]
31	Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83. [PMID: 7944078]
32	Multum Information Services, Inc. Expert Review Panel.
33	Radack KL, Deck CC, Bloomfield SS "Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen." Ann Intern Med 107 (1987): 628-35. [PMID: 2889416]
34	Ahmad S "Indomethacin-enalapril interaction: an alert." South Med J 84 (1991): 411-2. [PMID: 2000541]
35	Silberbauer K, Stanek B, Templ H "Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition." Br J Clin Pharmacol 14 (1982): s87-93. [PMID: 6753910]
36	Townend JN, Doran J, Lote CJ, Davies MK "Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril." Br Heart J 73 (1995): 434-41. [PMID: 7786658]
37	Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD "Risk of adverse gastrointestinal events from inhaled corticosteroids." Pharmacotherapy 28 (2008): 1325-34. [PMID: 18956992]
38	Koren G, Roifman C, Gelfand E, Lavi S, Suria D, Stein L "Corticosteroids-salicylate interaction in a case of juvenile rheumatoid arthritis." Ther Drug Monit 9 (1987): 177-9. [PMID: 3617157]
39	Piper JM, Ray WA, Daugherty JR, Griffin MR "Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs." Ann Intern Med 114 (1991): 735-40. [PMID: 2012355]
40	Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
41	Product Information. Avelox (moxifloxacin) Bayer, West Haven, CT.
42	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
43	Klinkhardt U, Kirchmaier CM, Westrup D, Graff J, Mahnel R, Breddin HK, Harder S "Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A." Clin Pharmacol Ther 67 (2000): 305-13. [PMID: 10741635]
44	Product Information. Plavix (clopidogrel). Bristol-Myers Squibb, Princeton, NJ.
45	Deray G, Le Hoang P, Aupetit B, Achour A, Rottembourg J, Baumelou A "Enhancement of cyclosporine A nephrotoxicity by diclofenac." Clin Nephrol 27 (1987): 213-4. [PMID: 2953512]
46	Sesin GP, O'Keefe E, Roberto P "Sulindac-induced elevation of serum cyclosporine concentration." Clin Pharm 8 (1989): 445-6. [PMID: 2663332]
47	Covington TR, Lawson LC, Young LL, eds. "Handbook of Nonprescription Drugs. 10th ed." Washington, DC: American Pharmaceutical Association (1993):.
48	Gaspari F, Vigano G, Locatelli M, Remuzzi G "Influence of antacid administrations on aspirin absorption in patients with chronic renal failure on maintenance hemodialysis." Am J Kidney Dis 11 (1988): 338-42
49	Levy G, Lampman T, Kamath BL, Garrettson LK "Decreased serum salicylate concentrations in children with rheumatic fever treated with antacid." N Engl J Med 293 (1975): 323-5
50	Rodin SM, Johnson BF "Pharmacokinetic interactions with digoxin." Clin Pharmacokinet 15 (1988): 227-44. [PMID: 3056649]
51	Finch MB, Johnston GD, Kelly JG, McDevitt DG "Pharmacokinetics of digoxin alone and in the presence of indomethacin therapy." Br J Clin Pharmacol 17 (1984): 353-5
52	Jorgensen HS, Christensen HR, Kampmann JP "Interaction between digoxin and indomethacin or ibuprofen." Br J Clin Pharmacol 31 (1991): 108-10
53	Ponce SP, Jennings AE, Madias NE, Harrington JT "Drug-induced hyperkalemia." Medicine (Baltimore) 64 (1985): 357-70. [PMID: 2865667]
54	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
55	Abdel-Haq B, Magagna A, Favilla S, Salvetti A "Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects." J Cardiovasc Pharmacol 18 (1991): s33-6. [PMID: 1725198]
56	Moore TJ, Crantz FR, Hollenberg NK "Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension." Hypertension 3 (1981): 168-73. [PMID: 6260645]
57	Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
58	Product Information. Remodulin (treprostinil). United Therapeutics Corp, Silver Spring, MD.
59	Product Information. Ventavis (iloprost). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
60	Hirsch J, Dalen J, Guyatt G, American College of Chest Physicians "The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Physicians." Chest 119(1 Suppl) (2001): 1S-2S. [PMID: 11157638]
61	Product Information. Integrilin (eptifibatide). Schering Laboratories, Kenilworth, NJ.
62	Cinquegrani MP, Liang CS "Indomethacin attenuates the hypotensive action of hydralazine." Clin Pharmacol Ther 39 (1986): 564-70
63	Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
64	Product Information. Apidra (insulin glulisine). Aventis Pharmaceuticals, Bridgewater, NJ.
65	Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1. [PMID: 6356848]
66	Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
67	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
68	Product Information. Sodium Iodide I-123 (sodium iodide I-123). GE Healthcare, Princeton, NJ.
69	Tietjen DP "Recurrence and specificity of nephrotic syndrome due to tolmetin." Am J Med 87 (1989): 354-5
70	Shand DG, Epstein C, Kinberg-Calhoun J, et al "The effect of etodolac administration on renal function in patients with arthritis." J Clin Pharmacol 26 (1986): 269-74
71	Turner GA, Walker RJ, Bailey RR, et al "Sulindac-induced acute interstitial nephritis." N Z Med J 97 (1984): 239-40
72	Product Information. Diovan (valsartan). Novartis Pharmaceuticals, East Hanover, NJ.
73	Product Information. Suclear (polyethylene glycol 3350 with electrolytes). Braintree Laboratories, Braintree, MA.
74	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
75	Product Information. Effient (prasugrel). Lilly, Eli and Company, Indianapolis, IN.
76	Harris M, Bryant LR, Danaher P, Alloway J "Effect of low dose daily aspirin on serum urate levels and urinary excretion in patients receiving probenecid for gouty arthritis." J Rheumatol 27 (2000): 2873-6. [PMID: 11128679]
77	Regal RE "Aspirin and uricosurics: interaction revisited." Drug Intell Clin Pharm 21 (1987): 219-20. [PMID: 3829916]
78	Product Information. Brilinta (ticagrelor). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
79	Dasgupta A, Jacques M "Reduced in vitro displacement of valproic acid from protein binding by salicylate in uremic sera compared with normal sera - role of uremic compounds." Am J Clin Pathol 101 (1994): 349-53. [PMID: 8135194]
80	Farrell K, Orr JM, Abbott FS, et al "The effect of acetylsalicylic acid on serum free valproate concentrations and valproate clearance in children." J Pediatr 101 (1982): 142-4. [PMID: 6806458]
81	Orr JM, Abbott FS, Farrell K, Ferguson S, Sheppard I, Godolphin W "Interaction between valproic acid and aspirin in epileptic children: serum protein binding and metabolic effects." Clin Pharmacol Ther 31 (1982): 642-9. [PMID: 6804150]
82	Bartoli E, Arras S, Faedda R, Soggia G, Satta A, Olmeo NA "Blunting of furosemide diuresis by aspirin in man." J Clin Pharmacol 20 (1980): 452-8
83	Valette H, Apoil E "Interaction between salicylate and two loop diuretics." Br J Clin Pharmacol 8 (1979): 592-4
84	Cheng Z, Radominska-Pandya A, Tephly TR. Studies on the substrate specificity of human intestinal UDP- lucuronosyltransferases 1A8 and 1A10. Drug Metab Dispos. 1999 Oct;27(10):1165-70.
85	Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
86	Saeed SA, Gilani AH "Antithrombotic activity of clove oil." J Pak Med Assoc 44 (1994): 112-5. [PMID: 8078176]
87	Srivasta KC "Antiplatelet principles from a food spice clove (Syzygium aromaticum L) [corrected]" Prostaglandins Leukot Essent Fatty Acids 48 (1993): 363-72. [PMID: 8321872]
88	Miner PB Jr, Fort JG, Zhang Y. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325?mg + immediate-release omeprazole 40?mg) or enteric-coated aspirin 325?mg + enteric-coated omeprazole 40?mg - a randomised, phase 1, crossover study.?Aliment Pharmacol Ther. 2013;38(1):62-71. [PMID: 23692061]
89	Inarrea P, Esteva F, Cornudella R, Lanas A "Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man." Scand J Gastroenterol 35 (2000): 242-6. [PMID: 10766315]
90	Nefesoglu FZ, Ayanoglu-Dulger G, Ulusoy NB, Imeryuz N "Interaction of omeprazole with enteric-coated salicylate tablets." Int J Clin Pharmacol Ther 36 (1998): 549-53. [PMID: 9799060]
91	Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32. [PMID: 9562227]
92	Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
93	Product Information. Vitrase (hyaluronidase). Bausch and Lomb, Rochester, NY.

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence